Immunogen (IMGN) Tops Q4 EPS by 1c

Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $39.45 million versus the consensus estimate of $32.71 million.

Financial Guidance

For 2018, ImmunoGen expects:

• revenues between $60 million and $65 million;
• operating expenses between $185 million and $190 million; and
• cash and cash equivalents at December 31, 2018 between $115 million and $120 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Waller: Recent Increases In Core Inflation Are Quite Broad
• Sanuwave Q2 2026 revenue tops revised guidance range